SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J 1983; 287: 10889.
  • 2
    Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 4869.
  • 3
    Petri M. In: The antiphospholipid syndrome. II: Autoimmune thrombosis. AshersonRA, CerveraR, PietteJ, ShoenfeldY, editors. 2nd ed. Amsterdam: Elsevier Science; 2002. p. 1120.
  • 4
    Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 101927.
  • 5
    Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, et al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68: 36674.
  • 6
    Morrow WJW, Nelson L, Watts R, Isenberg DA. Autoimmune rheumatic disease. 2nd ed. Oxford: Oxford University Press; 1999.
  • 7
    Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 1998; 7: 36.
  • 8
    Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 9937.
  • 9
    Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68: 35365.
  • 10
    Lynch A, Marlar R, Murphy J, Davila G, Santos M, Rutledge J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome: a prospective study. Ann Intern Med 1994; 120: 4705.
  • 11
    Pierangeli SS, Harris EN. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus 1994; 3: 24751.
  • 12
    Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A 1991; 88: 306973.
  • 13
    Ikematsu W, Luan FL, La Rosa L, Beltrami B, Nicoletti F, Buyon JP, et al. Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice. Arthritis Rheum 1998; 41: 102639.
  • 14
    Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 15447.
  • 15
    McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87: 41204.
  • 16
    Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 1778.
  • 17
    Ordi J, Selva A, Monegal F, Porcel JM, Martinez-Costa X, Vilardell M. Anticardiolipin antibodies and dependence of a serum cofactor: a mechanism of thrombosis. J Rheumatol 1993; 20: 13214.
  • 18
    Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S, et al. Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 146674.
  • 19
    McNally T, Mackie IJ, Machin SJ, Isenberg DA. Increased levels of beta 2 glycoprotein-I antigen and beta 2 glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br J Rheumatol 1995; 34: 10316.
  • 20
    Kandiah DA, Sali A, Sheng Y, Victoria EJ, Marquis DM, Coutts SM, et al. Current insights into the “antiphospholipid” syndrome: clinical, immunological, and molecular aspects. Adv Immunol 1998; 70: 50763.
  • 21
    Loizou S, Mackworth-Young CG, Cofiner C, Walport MJ. Heterogeneity of binding reactivity to different phospholipids of antibodies from patients with systemic lupus erythematosus (SLE) and with syphilis. Clin Exp Immunol 1990; 80: 1716.
  • 22
    Di Simone N, Meroni PL, de Papa N, Raschi E, Caliandro D, De Carolis CS, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered β2-glycoprotein I. Arthritis Rheum 2000; 43: 14050.
  • 23
    Shoenfeld Y, Gharavi A, Koike T. β2GP-I in the anti phospholipid (Hughes') syndrome—from a cofactor to an autoantigen—from induction to prevention of antiphospholipid syndrome. Lupus 1998; 7: 5036.
  • 24
    Koike T, Ichikawa K, Kasahara H, Atsumi T, Tsutsumi A, Matsuura E. Epitopes on β2-GPI recognized by anticardiolipin antibodies. Lupus 1998; 7: S147.
  • 25
    Roubey RA, Eisenberg RA, Harper MF, Winfield JB. “Anticardiolipin” autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid: importance of Ag density and bivalent binding. J Immunol 1995; 154: 95460.
  • 26
    Bouma B, de Groot PG, van den Elsen JM, Ravelli RB, Schouten A, Simmelink MJ, et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 516674.
  • 27
    Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, et al. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18: 622839.
  • 28
    Hammel M, Kriechbaum M, Gries A, Kostner GM, Laggner P, Prassl R. Solution structure of human and bovine beta(2)-glycoprotein I revealed by small-angle X-ray scattering. J Mol Biol 2002; 321: 8597.
  • 29
    Inanc M, Radway-Bright EL, Isenberg DA. β2-glycoprotein I and anti-β2-glycoprotein I antibodies: where are we now? Br J Rheumatol 1997; 36: 124757.
  • 30
    Schultze HE, Heide K, Haupt H. Über ein bisher unbekanntes niedermolekulares Beta2-Globulin des Humanserums. Naturwissenschaften 1961; 48: 719.
  • 31
    Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci U S A 1984; 81: 36404.
  • 32
    Steinkasserer A, Estaller C, Weiss EH, Sim RB, Day AJ. Complete nucleotide and deduced amino acid sequence of human beta 2- glycoprotein I. Biochem J 1991; 277: 38791.
  • 33
    Schousboe I. β2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 108691.
  • 34
    Nimpf J, Bevers EM, Bomans PH, Till U, Wurm H, Kostner GM, et al. Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. Biochim Biophys Acta 1986; 884: 1429.
  • 35
    Nimpf J, Wurm H, Kostner GM. Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987; 63: 10914.
  • 36
    Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 56973.
  • 37
    Pittoni V, Ravirajan CT, Donohoe S, Maclin SJ, Lydyard PM, Isenberg DA. Human monoclonal anti-phospholipid antibodies selectively bind to membrane phospholipid and beta2-glycoprotein I (beta2-GPI) on apoptotic cells. Clin Exp Immunol 2000; 119: 53343.
  • 38
    Chonn A, Semple SC, Cullis PR. Beta 2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of “non-self” particles. J Biol Chem 1995; 270: 258459.
  • 39
    Roubey RA. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39: 144454.
  • 40
    Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, et al. Endothelial cells as target for antiphospholipid antibodies: human polyclonal and monoclonal anti–β2-glycoprotein I antibodies react in vitro with endothelial cells through adherent β2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997; 40: 55161.
  • 41
    Meroni PL, Del Papa N, Raschi E, Panzeri P, Borghi MO, Tincani A, et al. Beta2-glycoprotein I as a ‘cofactor’ for anti-phospholipid reactivity with endothelial cells. Lupus 1998; 7: S447.
  • 42
    Roman MJ, Salmon JE, Sobel R, Lockshin MD, Sammaritano L, Schwartz JE, et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol 2001; 87: 6636.
  • 43
    Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002; 11: 20814.
  • 44
    Petri M. 1998 update on antiphospholipid antibodies. Curr Opin Rheumatol 1998; 10: 42630.
  • 45
    Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 22119.
  • 46
    Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 19972002.
  • 47
    Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, et al. Antibodies to high-density lipoprotein and β2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002; 46: 268694.
  • 48
    Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 45762.
  • 49
    Chamley LW, Duncalf AM, Konarkowska B, Mitchell MD, Johnson PM. Conformationally altered beta 2-glycoprotein I is the antigen for anti-cardiolipin autoantibodies. Clin Exp Immunol 1999; 115: 5716.
  • 50
    Borchman D, Harris EN, Pierangeli SS, Lamba OP. Interactions and molecular structure of cardiolipin and beta 2-glycoprotein 1 (beta 2-GP1). Clin Exp Immunol 1995; 102: 3738.
  • 51
    Subang R, Levine JS, Janoff AS, Davidson SM, Taraschi TF, Koike T, et al. Phospholipid-bound beta 2-glycoprotein I induces the production of anti-phospholipid antibodies. J Autoimmun 2000; 15: 2132.
  • 52
    Hammel M, Schwarzenbacher R, Gries A, Kostner GM, Laggner P, Prassl R. Mechanism of the interaction of beta(2)-glycoprotein I with negatively charged phospholipid membranes. Biochemistry 2001; 40: 1417381.
  • 53
    Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci U S A 1993; 90: 21415.
  • 54
    Hunt J, Krilis S. The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994; 152: 6539.
  • 55
    Matsuura E, Inagaki J, Kasahara H, Yamamoto D, Atsumi T, Kobayashi K, et al. Proteolytic cleavage of beta(2)-glycoprotein I: reduction of antigenicity and the structural relationship. Int Immunol 2000; 12: 118392.
  • 56
    Reddel SW, Wang YX, Krilis SA. Anti-beta2-glycoprotein I autoantibodies require an antigen density threshold, consistent with divalent binding. Lupus 2003; 12: 3745.
  • 57
    Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998; 95: 155426.
  • 58
    Sheng Y, Kandiah DA, Krilis SA. Anti-beta 2-glycoprotein I autoantibodies from patients with the “antiphospholipid” syndrome bind to beta 2-glycoprotein I with low affinity: dimerization of beta 2-glycoprotein I induces a significant increase in anti-beta 2-glycoprotein I antibody affinity. J Immunol 1998; 161: 203843.
  • 59
    Regnault V, Arvieux J, Vallar L, Lecompte T. Both kinetic data and epitope mapping provide clues for understanding the anti-coagulant effect of five murine monoclonal antibodies to human beta2-glycoprotein I. Immunology 1999; 97: 4007.
  • 60
    Keeling DM, Wilson AJ, Mackie IJ, Machin SJ, Isenberg DA. Some ‘antiphospholipid antibodies’ bind to beta 2-glycoprotein I in the absence of phospholipid. Br J Haematol 1992; 82: 5714.
  • 61
    Martinuzzo ME, Forastiero RR, Carreras LO. Anti beta 2 glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol 1995; 89: 397402.
  • 62
    Guerin J, Sim R, Yu BB, Ferluga J, Feighery C, Jackson J. Heterogeneous recognition of beta 2-glycoprotein I by antibodies from antiphospholipid syndrome patients. Thromb Haemost 2000; 84: 37480.
  • 63
    Balestrieri G, Tincani A, Spatola L, Allegri F, Prati E, Cattaneo R, et al. Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? Lupus 1995; 4: 12230.
  • 64
    Viard JP, Amoura Z, Bach JF. Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93: 1816.
  • 65
    Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen. J Immunol Methods 1991; 143: 2239.
  • 66
    Forastiero RR, Martinuzzo ME, Carreras LO. Binding properties of antibodies to prothrombin and beta2-glycoprotein I (beta2-GPI) assayed by ELISA and dot blot. Clin Exp Immunol 1999; 118: 4806.
  • 67
    Tincani A, Spatola L, Prati E, Allegri F, Ferremi P, Cattaneo R, et al. The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. J Immunol 1996; 157: 57328.
  • 68
    Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899906.
  • 69
    Sorice M, Circella A, Griggi T, Garofalo T, Nicodemo G, Pittoni V, et al. Anticardiolipin and anti-beta 2-GPI are two distinct populations of autoantibodies. Thromb Haemost 1996; 75: 3038.
  • 70
    Pierangeli SS, Harris EN, Davis SA, DeLorenzo G. Beta 2-glycoprotein 1 (beta 2GP1) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies. Br J Haematol 1992; 82: 56570.
  • 71
    Permpikul P, Rao LV, Rapaport SI. Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994; 83: 287892.
  • 72
    Harris EN. Syndrome of the black swan. Br J Rheumatol 1987; 26: 3246.
  • 73
    Alarcon-Segovia D, Cabral AR. Antiphospholipid antibodies. Where do they come from? Where do they go?. J Rheumatol 1994; 21: 9829.
  • 74
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 75
    Sheng Y, Sali A, Herzog H, Lahnstein J, Krilis SA. Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol 1996; 157: 374451.
  • 76
    Gharavi AE, Sammaritano LR, Wen J, Elkon KB. Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest 1992; 90: 11059.
  • 77
    Gharavi AE, Pierangeli SS, Colden-Stanfield M, Liu XW, Espinola RG, Harris EN. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol 1999; 163: 29227.
  • 78
    Gharavi AE, Pierangeli SS, Espinola RG, Liu X, Colden-Stanfield M, Harris EN. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002; 46: 54552.
  • 79
    Wang MX, Kandiah DA, Ichikawa K, Khamashta M, Hughes G, Koike T, et al. Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J Immunol 1995; 155: 162936.
  • 80
    Igarashi M, Matsuura E, Igarashi Y, Nagae H, Ichikawa K, Triplett DA, et al. Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood 1996; 87: 326270.
  • 81
    George J, Gilburd B, Hojnik M, Levy Y, Langevitz P, Matsuura E, et al. Target recognition of beta2-glycoprotein I (beta2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of beta2GPI in antibody binding. J Immunol 1998; 160: 391723.
  • 82
    Koike T, Ichikawa K, Atsumi T, Kasahara H, Matsuura E. β2-glycoprotein I–anti-β2-glycoprotein I interaction. J Autoimmun 2000; 15: 97100.
  • 83
    Iverson GM, Matsuura E, Victoria EJ, Cockerill KA, Linnik MD. The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI autoantibodies by ELISA. J Autoimmun 2002; 18: 28997.
  • 84
    Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci U S A 1999; 96: 51648.
  • 85
    George J, Blank M, Levy Y, Meroni P, Damianovich M, Tincani A, et al. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 1998; 97: 9006.
  • 86
    Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun 2000; 15: 916.
  • 87
    McNeeley PA, Dlott JS, Furie RA, Jack RM, Ortel TL, Triplett DA, et al. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost 2001; 86: 5905.
  • 88
    Sheng Y, Hanly JG, Reddel SW, Kouts S, Guerin J, Koike T, et al. Detection of ‘antiphospholipid’ antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding beta(2)- glycoprotein I and prothrombin. Clin Exp Immunol 2001; 124: 5028.
  • 89
    Giles IP, Haley JD, Nagl S, Isenberg DA, Latchman DS, Rahman A. A systematic analysis of sequences of human antiphospholipid and anti-beta2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs. Semin Arthritis Rheum 2003; 32: 24665.
  • 90
    Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001; 28: 25765.
  • 91
    Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003; 48: 44254.
  • 92
    Iverson GM, Jones DS, Marquis D, Linnik MD, Victoria EJ. A chemically defined, toleragen-based approach for targeting anti-beta2-glycoprotein I antibodies. Lupus 1998; 7: S1669.
  • 93
    Jones DS, Cockerill KA, Gamino CA, Hammaker JR, Hayag MS, Iverson GM, et al. Synthesis of LJP 993, a multivalent conjugate of the N-terminal domain of beta2GPI and suppression of an anti-beta2GPI immune response. Bioconjug Chem 2001; 12: 101220.